Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Therasphere Clear all
Completed Not applicable Interventional

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

NCT01176604
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Yttrium Y 90 Glass Microspheres
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 4, 2026, 4:37 AM EDT
Not listed Phase 2 Interventional

Definitive Therapy for Oligometastatic Solid Malignancies

NCT01898962
View directory record Official record
Conditions
Stage IV or Recurrent Carcinoma or Sarcoma
Interventions
Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose, Subtotal surgical removal plus ablative radiation dose, Radioembolization
Procedure · Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • Boulder, Colorado • Littleton, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 3 Interventional

Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery

NCT00109954
View directory record Official record
Conditions
Liver Cancer
Interventions
cisplatin, brachytherapy, yttrium Y 90 glass microspheres
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 4, 2026, 4:37 AM EDT
Approved For Marketing No phase listed Expanded access

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

NCT00906984
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Primary Liver Cancer
Interventions
TheraSphere
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 4, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

NCT03896646
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Computed Tomography, Hepatobiliary Iminodiacetic Acid Scan, Single Photon Emission Computed Tomography, Yttrium Y 90 Glass Microspheres, Yttrium-90 Microsphere Radioembolization
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer

NCT02837029
View directory record Official record
Conditions
Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres
Other · Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

NCT00956930
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres, Doxorubicin
Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

NCT01253148
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
TheraSphere® Yttrium-90 (Y-90) Microspheres
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Early Phase 1 Interventional

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

NCT01730157
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Early Phase 1 Interventional

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

NCT02072356
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
yttrium Y 90 glass microspheres, laboratory biomarker analysis, TheraSphere
Radiation · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
8 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Not applicable Interventional

TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis

NCT01556282
View directory record Official record
Conditions
Liver Cancer, Portal Vein Thrombosis
Interventions
TheraSphere
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma

NCT01290523
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated No phase listed Observational

RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry

NCT03516695
View directory record Official record
Conditions
Liver Cancer
Interventions
TheraSphere®
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Los Angeles, California • Coral Gables, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 4, 2026, 4:37 AM EDT
Recruiting Phase 1 Interventional

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

NCT05303467
View directory record Official record
Conditions
Glioblastoma Multiforme, Recurrent Glioblastoma
Interventions
TheraSphere GBM
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

NCT03109262
View directory record Official record
Conditions
Primary Malignant Liver Neoplasm
Interventions
Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres, Technetium 99mTc albumin aggregated (99mTc-MAA), Single-photon emission computerized tomography (SPECT) scan
Procedure · Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Early Phase 1 Interventional

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

NCT03812562
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Yttrium Y 90 Glass Microspheres
Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 4, 2026, 4:37 AM EDT
Approved For Marketing No phase listed Expanded access

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

NCT01076517
View directory record Official record
Conditions
Liver Cancer
Interventions
Therasphere
Device
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 4, 2026, 4:37 AM EDT
No Longer Available No phase listed Expanded access

Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer

NCT00701168
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Neoplasm Metastasis
Interventions
yttrium Y 90 microspheres (Therasphere®)
Device
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
19 Years and older
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 4, 2026, 4:37 AM EDT
No Longer Available No phase listed Expanded access

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

NCT02960620
View directory record Official record
Conditions
Liver Cancer, Liver Neoplasms, HepatoCellular Carcinoma
Interventions
TheraSphere Treatment
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 4, 2026, 4:37 AM EDT
Recruiting Not applicable Interventional

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

NCT05953961
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Therasphere 90Y, Microwave Ablation
Device
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 4, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

NCT04108481
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
Interventions
Durvalumab, Yttrium-90 RadioEmbolization
Drug · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 4, 2026, 4:37 AM EDT
Completed No phase listed Observational

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

NCT00532740
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
Yttrium Y 90 glass microspheres
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 4, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

NCT06192758
View directory record Official record
Conditions
Prostate, Cancer
Interventions
TheraSphere PCa
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 4, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

TheraSphere® For Treatment of Metastases in Liver

NCT04517643
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Colorectal Cancer
Interventions
Therasphere Therapy
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 4, 2026, 4:37 AM EDT